Literature DB >> 8201014

The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.

D J Rader1, W Cain, K Ikewaki, G Talley, L A Zech, D Usher, H B Brewer.   

Abstract

Lipoprotein(a) (Lp[a]) is an atherogenic lipoprotein which is similar in structure to low density lipoproteins (LDL) but contains an additional protein called apolipoprotein(a) (apo[a]). Apo(a) is highly polymorphic in size, and there is a strong inverse association between the size of the apo(a) isoform and the plasma concentration of Lp(a). We directly compared the in vivo catabolism of Lp(a) particles containing different size apo(a) isoforms to establish whether there is an effect of apo(a) isoform size on the catabolic rate of Lp(a). In the first series of studies, four normal subjects were injected with radio-labeled S1-Lp(a) and S2-Lp(a) and another four subjects were injected with radiolabeled S2-Lp(a) and S4-Lp(a). No significant differences in fractional catabolic rate were found between Lp(a) particles containing different apo(a) isoforms. To confirm that apo(a) isoform size does not influence the rate of Lp(a) catabolism, three subjects heterozygous for apo(a) were selected for preparative isolation of both Lp(a) particles. The first was a B/S3-apo(a) subject, the second a S4/S6-apo(a) subject, and the third an F/S3-apo(a) subject. From each subject, both Lp(a) particles were preparatively isolated, radiolabeled, and injected into donor subjects and normal volunteers. In all cases, the catabolic rates of the two forms of Lp(a) were not significantly different. In contrast, the allele-specific apo(a) production rates were more than twice as great for the smaller apo(a) isoforms than for the larger apo(a) isoforms. In a total of 17 studies directly comparing Lp(a) particles of different apo(a) isoform size, the mean fractional catabolic rate of the Lp(a) with smaller size apo(a) was 0.329 +/- 0.090 day-1 and of the Lp(a) with the larger size apo(a) 0.306 +/- 0.079 day-1, not significantly different. In summary, the inverse association of plasma Lp(a) concentrations with apo(a) isoform size is not due to differences in the catabolic rates of Lp(a) but rather to differences in Lp(a) production rates.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8201014      PMCID: PMC294537          DOI: 10.1172/JCI117292

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  Semi-automated enzyme-linked immunosorbent assay (ELISA) for the quantification of apolipoprotein B using monoclonal antibodies.

Authors:  M Bojanovski; R E Gregg; D M Wilson; H B Brewer
Journal:  Clin Chim Acta       Date:  1987-12       Impact factor: 3.786

2.  Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma.

Authors:  G Utermann; H J Menzel; H G Kraft; H C Duba; H G Kemmler; C Seitz
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

3.  Molecular weight determination of protein-dodecyl sulfate complexes by gel electrophoresis in a discontinuous buffer system.

Authors:  D M Neville
Journal:  J Biol Chem       Date:  1971-10-25       Impact factor: 5.157

4.  Human plasma lipoprotein [a]. Structural properties.

Authors:  J W Gaubatz; C Heideman; A M Gotto; J D Morrisett; G H Dahlen
Journal:  J Biol Chem       Date:  1983-04-10       Impact factor: 5.157

5.  Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods.

Authors:  K Ikewaki; D J Rader; J R Schaefer; T Fairwell; L A Zech; H B Brewer
Journal:  J Lipid Res       Date:  1993-12       Impact factor: 5.922

6.  Heterogeneity of human plasma lipoprotein (a). Isolation and characterization of the lipoprotein subspecies and their apoproteins.

Authors:  G M Fless; C A Rolih; A M Scanu
Journal:  J Biol Chem       Date:  1984-09-25       Impact factor: 5.157

7.  Isolation of apolipoprotein(a) from lipoprotein(a).

Authors:  G M Fless; M E ZumMallen; A M Scanu
Journal:  J Lipid Res       Date:  1985-10       Impact factor: 5.922

8.  Lp(a) lipoprotein as a risk factor for myocardial infarction.

Authors:  G G Rhoads; G Dahlen; K Berg; N E Morton; A L Dannenberg
Journal:  JAMA       Date:  1986-11-14       Impact factor: 56.272

9.  Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.

Authors:  G H Dahlen; J R Guyton; M Attar; J A Farmer; J A Kautz; A M Gotto
Journal:  Circulation       Date:  1986-10       Impact factor: 29.690

10.  The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels.

Authors:  V W Armstrong; P Cremer; E Eberle; A Manke; F Schulze; H Wieland; H Kreuzer; D Seidel
Journal:  Atherosclerosis       Date:  1986-12       Impact factor: 5.162

View more
  37 in total

1.  Lipoprotein (a) metabolism estimated by nonsteady-state kinetics.

Authors:  K G Parhofer; T Demant; M M Ritter; H C Geiss; M Donner; P Schwandt
Journal:  Lipids       Date:  1999-04       Impact factor: 1.880

Review 2.  Update on lipoprotein(a) as a cardiovascular risk factor and mediator.

Authors:  Michael B Boffa; Marlys L Koschinsky
Journal:  Curr Atheroscler Rep       Date:  2013-10       Impact factor: 5.113

3.  A genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population.

Authors:  Yibin Liu; Hongkun Ma; Qian Zhu; Bin Zhang; Hong Yan; Hanping Li; Jinxiu Meng; Weihua Lai; Liwen Li; Danqing Yu; Shilong Zhong
Journal:  J Lipid Res       Date:  2019-06-11       Impact factor: 5.922

Review 4.  Lipoprotein (a): a historical appraisal.

Authors:  Karam M Kostner; Gert M Kostner
Journal:  J Lipid Res       Date:  2016-11-07       Impact factor: 5.922

Review 5.  Structure, function, and genetics of lipoprotein (a).

Authors:  Konrad Schmidt; Asma Noureen; Florian Kronenberg; Gerd Utermann
Journal:  J Lipid Res       Date:  2016-04-13       Impact factor: 5.922

Review 6.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

Review 7.  Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.

Authors:  Adam N Berman; Ron Blankstein
Journal:  Curr Cardiol Rep       Date:  2019-08-05       Impact factor: 2.931

8.  Distinct metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein(a).

Authors:  Margaret R Diffenderfer; Stefania Lamon-Fava; Santica M Marcovina; P Hugh R Barrett; Julian Lel; Gregory G Dolnikowski; Lars Berglund; Ernst J Schaefer
Journal:  Metabolism       Date:  2015-11-06       Impact factor: 8.694

Review 9.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

10.  Dimyristoylphosphotidylcholine induces conformational changes in apoB that lowers lipoprotein(a).

Authors:  Yan-Ting Wang; Anne von Zychlinski; Sally P A McCormick
Journal:  J Lipid Res       Date:  2008-12-19       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.